Caprock Group LLC Has $376,000 Holdings in Illumina, Inc. (NASDAQ:ILMN)

Caprock Group LLC increased its stake in shares of Illumina, Inc. (NASDAQ:ILMN) by 3.0% during the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 2,884 shares of the life sciences company’s stock after acquiring an additional 83 shares during the period. Caprock Group LLC’s holdings in Illumina were worth $376,000 as of its most recent SEC filing.

Several other institutional investors have also added to or reduced their stakes in the stock. O Shaughnessy Asset Management LLC boosted its position in shares of Illumina by 91.7% during the first quarter. O Shaughnessy Asset Management LLC now owns 4,199 shares of the life sciences company’s stock worth $577,000 after buying an additional 2,009 shares during the period. Canada Pension Plan Investment Board grew its stake in shares of Illumina by 154.9% during the 1st quarter. Canada Pension Plan Investment Board now owns 279,351 shares of the life sciences company’s stock worth $38,360,000 after acquiring an additional 169,756 shares in the last quarter. SVB Wealth LLC raised its holdings in shares of Illumina by 6.8% in the first quarter. SVB Wealth LLC now owns 3,277 shares of the life sciences company’s stock valued at $450,000 after purchasing an additional 209 shares during the last quarter. Jacobs Levy Equity Management Inc. lifted its position in shares of Illumina by 19.6% in the first quarter. Jacobs Levy Equity Management Inc. now owns 497,274 shares of the life sciences company’s stock worth $68,286,000 after purchasing an additional 81,378 shares in the last quarter. Finally, Iron Triangle Partners LP boosted its holdings in Illumina by 50.3% during the first quarter. Iron Triangle Partners LP now owns 330,758 shares of the life sciences company’s stock worth $45,420,000 after purchasing an additional 110,758 shares during the last quarter. 89.42% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

Several equities research analysts have commented on ILMN shares. Barclays boosted their price target on shares of Illumina from $135.00 to $145.00 and gave the stock an “equal weight” rating in a research report on Tuesday, November 5th. JPMorgan Chase & Co. increased their price target on Illumina from $125.00 to $140.00 and gave the company a “neutral” rating in a research report on Tuesday, November 5th. Citigroup boosted their price target on Illumina from $155.00 to $190.00 and gave the stock a “buy” rating in a research report on Tuesday, November 5th. Scotiabank cut their price objective on Illumina from $176.00 to $164.00 and set a “sector outperform” rating for the company in a report on Thursday, August 15th. Finally, UBS Group boosted their target price on shares of Illumina from $133.00 to $145.00 and gave the stock a “neutral” rating in a report on Tuesday, November 5th. One equities research analyst has rated the stock with a sell rating, eight have given a hold rating, fourteen have given a buy rating and two have given a strong buy rating to the company’s stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $164.00.

Illumina Stock Performance

ILMN opened at $140.14 on Friday. The company has a debt-to-equity ratio of 0.94, a current ratio of 2.43 and a quick ratio of 1.85. The business has a fifty day simple moving average of $140.61 and a 200 day simple moving average of $124.84. Illumina, Inc. has a 1 year low of $93.51 and a 1 year high of $156.66. The company has a market capitalization of $22.23 billion, a PE ratio of -14.07 and a beta of 1.13.

Illumina (NASDAQ:ILMN) last announced its earnings results on Monday, November 4th. The life sciences company reported $1.14 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.88 by $0.26. Illumina had a negative net margin of 36.10% and a positive return on equity of 7.29%. The company had revenue of $1.08 billion during the quarter, compared to analysts’ expectations of $1.08 billion. During the same quarter in the previous year, the business posted $0.33 earnings per share. Illumina’s quarterly revenue was down 3.5% on a year-over-year basis. Research analysts expect that Illumina, Inc. will post 4.11 EPS for the current year.

Illumina Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.